Case Report Open Access
Copyright ©The Author(s) 2005. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2005; 11(28): 4445-4446
Published online Jul 28, 2005. doi: 10.3748/wjg.v11.i28.4445
Ovarian carcinoma in two patients with chronic liver disease
Mehlika Isildak, Gulay Sain Guven, Murat Kekilli, Yavuz Beyazit, Mustafa Erman, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey
Gulay Sain Guven, Department of Internal Medicine, Section of General Internal Medicine, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey
Mustafa Erman, Department of Internal Medicine, Section of Medical Oncology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Gülay Sain Guven, Department of Internal Medicine, Section of General Internal Medicine, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey. gsain@tr.net
Telephone: +90-312-305-3029 Fax: +90-312-305-2302
Received: July 23, 2004
Revised: November 23, 2004
Accepted: December 1, 2004
Published online: July 28, 2005

Abstract

Ascites is a common and debilitating complication of cirrhosis. However, patients with chronic liver disease are not spared from other causes of ascites and physicians should be careful not to miss an underlying malignancy. Ovarian cancer is an insidious disease, which is difficult to diagnose and it ranks first in mortality among all gynecological cancers. Here, we present two cases of patients with chronic liver disease that developed ascites not simply because of cirrhosis but as a manifestation of ovarian cancer. We would like to emphasize that the causes of ascites, other than the liver itself, should not be overlooked in patients with chronic liver disease.

Key Words: Ovarian carcinoma, Ascites, Chronic liver disease



INTRODUCTION

Ascites is the most common complication of viral, alcoholic or metabolic liver cirrhosis. Approximately half of the cirrhotic patients are expected to develop ascites within 10 years after the diagnosis[1]. Development of ascites is an important prog-nostic sign in the usual course of chronic liver disease since it shortens the 5-year survival rate of a cirrhotic patient[2-4].

Ascites may develop in 75% of all patients with liver disease. The remaining 25% is due to malignancy (10%), cardiac failure (3%), pancreatitis (1%), tuberculosis (2%) and other uncommon causes[5]. However, it is important to comprehend that cirrhotic patients are not spared from these non-cirrhotic causes. Herein we present two patients with chronic liver disease who were diagnosed to have ovarian cancer after a thorough investigation of their ascites.

CASE REPORT
Case 1

A 45-year-old woman with chronic liver disease was seen at the outpatient clinic, because of her recent complaints. She complained of abdominal swelling, in the previous 2 mo. She had abdominal pain radiating to her back, which was aggravated after meals. Famotidine was of no use in relieving the pain. She also complained of weight loss as much as 5 kg in 20 d. The patient had been followed up for chronic hepatitis B infection for 8 years. The diagnosis was confirmed with a liver biopsy, which showed cirrhosis at developmental stage. She underwent esophageal variceal band ligation and transjugular intrahepatic portosystemic shunt (TIPSS) for the management of chronic ascites before 5 years. TIPSS was performed once again before 3 years. She received medical treatment while awaiting liver transplantation. She had no evident family history.

Physical examination revealed that she had massive ascites and was admitted to our hospital for further investigation. Ultrasonographic examination of the abdomen had no remarkable finding except ascites and parenchymal changes in the liver. Hepatic and portal venous systems were normal since the portosystemic shunt functioned well. Diagnostic paracentesis was performed and biochemical analysis was as follows: LDH: 318 U/L (concomitant serum LDH was 337 U/L), albumin: 2.4 g/dL (serum albumin: 2.9 g/dL). Cytological investigation of the ascites showed malignant cells. Abdominal computed tomography (CT) revealed peritoneal carcinomatosis and solid mass lesions of both the ovaries. CT of the thorax showed metastatic nodules on the pleural surface. Serum CA 125 level was 9 853 U/mL.

The patient underwent total abdominal hysterectomy, bilateral salpingo-oopherectomy, omentectomy, and pelvic–paraaortic lymph node dissection. Tumor debulking surgery and histopathological examination of the specimens reported that she had ovarian serous papillary adenocarcinoma (stage III). Paclitaxel–carboplatin therapy was started. Unfortunately, during the first course of chemotherapy she developed acute pneumonia and empyema, which rapidly progressed to septic shock leading to her death.

Case 2

A 40-year-old woman was admitted to hospital because of ascites. She was also suffering from loss of weight and appetite in the last 10 d. She was known to have had chronic hepatitis B and D. She received interferon treatment for 6 mo, followed by another course of pegylated interferon 2 years later. She had no significant complication of chronic liver disease.

Biochemical analysis of ascites showed an LDH level of 564 U/L and serum-ascites albumin gradient was 0.7. Computed tomography of the abdomen showed massive ascites, omental cake sign and mass lesions of 4-5 cm in both adnexal regions. Serum CA 125 level was 3 028 U/mL. She underwent total abdominal hysterectomy, bilateral oophor-ectomy, lymph node dissection and tumor debulking surgery. Pathological diagnosis of the tumor was poorly differentiated adenocarcinoma, which was positive for CA 125 and CK7, thus confirming an ovarian origin. Serum CA 125 value of the patient decreased to 25.9 U/mL after the operation.

DISCUSSION

Ovarian carcinoma is difficult to diagnose and it is usually discovered only in its advanced stages. It therefore has the highest mortality among all gynecological malignancies. Cachexia with pelvic mass, ascites and elevated CA125 levels generally lead to its correct diagnosis, but usually there are no pathognomonic radiological or laboratory findings. Therefore, a laparatomy is usually necessary for its final diagnosis.

In the majority of ovarian cancer cases, the etiology is unknown. A small percentage of cases may be attributed to hereditary disorders. Close follow-up with annual transvaginal ultrasound examination and measurement of CA125 levels is advocated for patients with high at genetic risk. Prophylactic oophorectomy after completion of fertility may be a reasonable option for BRCA mutation carriers and might be effective in preventing both ovarian or breast cancers. However, such an approach has not been evaluated[6]. Multiple pregnancies or the use of oral contraceptives might have a protective effect as they can reduce ovulation and related hormonal effect[7].

The 5-year survival rate for advanced disease is about 30%. In a study reviewing the general practice records of patients with epithelial ovarian cancer, the most frequent symptoms are abdominal pain, change in bowel habits, abdominal swelling, vaginal bleeding, weight loss, and backache[8]. The same study revealed that the most significant independent variable for survival is the stage of the disease at surgery[8].

Ascites is an important clinical finding in ovarian cancer. Any patient who presents with ascites should undergo a thorough investigation of ascites influencing cytological analysis and measurement of amylase level. Though an elevated CA125 level should raise a suspicion of ovarian cancer, its interpretation in patients with any serosal involvement may not be easy, since any type of pleural, peritoneal or pericardial irritation can lead to elevated serum level of this high molecular weight glycoprotein[9].

CA125 level greater than 35 U/mL has been reported in 35-75% of cirrhotic patients, most commonly in those with ascites. Studies have shown that cirrhotic patients with ascites have different mean serum CA125 levels of 291 and 572 U/mL, respectively[10-12]. All these data show that CA125 is not a strong diagnostic tool for ovarian cancer in patients with preexisting cirrhotic ascites.

Though it is not possible to define a strict dividing line between “expected” and “alarming” ascites during the course of chronic liver disease, some clues may help physicians to find other underlying causes. We believe that the two cases in our study contribute to this. The first patient had a rapid development of ascites despite a functional TIPSS. The other patient did not have overt signs of cirrhotic changes of the liver, the reason why ascites occurred is not clear. In both cases, the presence of an exudative rather than transudative peritoneal fluid is another underlying cause other than cirrhosis[13]. As mentioned above, an elevated CA125 level is not a specific diagnostic marker for ovarian cancer as it may be elevated in a cirrhotic patient, due to peritoneal irritation. Thus, extremely high CA125 levels merit further investigation.

We conclude that the development of ascites in patients with chronic liver disease should never be considered as “normal” and a search for other causes should be considered. Prompt diagnosis and surgical intervention may be life-saving in such cases.

Footnotes

Science Editor Wang XL Language Editor Elsevier HK

References
1.  Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, Porayko M, Moreau R, Garcia-Tsao G. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258-266.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 602]  [Cited by in F6Publishing: 564]  [Article Influence: 26.9]  [Reference Citation Analysis (0)]
2.  Saunders JB, Walters JR, Davies AP, Paton A. A 20-year prospective study of cirrhosis. Br Med J (Clin Res Ed). 1981;282:263-266.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 274]  [Cited by in F6Publishing: 273]  [Article Influence: 6.3]  [Reference Citation Analysis (0)]
3.  Llach J, Ginès P, Arroyo V, Rimola A, Titó L, Badalamenti S, Jiménez W, Gaya J, Rivera F, Rodés J. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988;94:482-487.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Salerno F, Borroni G, Moser P, Badalamenti S, Cassarà L, Maggi A, Fusini M, Cesana B. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol. 1993;88:514-519.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Reynolds TB. Ascites. Clin Liver Dis. 2000;4:151-168, vii.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 33]  [Cited by in F6Publishing: 35]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
6.  Anderiesz C, Quinn MA. Screening for ovarian cancer. Med J Aust. 2003;178:655-656.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Molpus KL, Jones HW 3rd. Gynecological Cancers. Cecil Textbook of Medicine. Philadelphia: WB Saunders 2004; 1238-1241.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Kirwan JM, Tincello DG, Herod JJ, Frost O, Kingston RE. Effect of delays in primary care referral on survival of women with epithelial ovarian cancer: retrospective audit. BMJ. 2002;324:148-151.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 49]  [Cited by in F6Publishing: 51]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
9.  Sevinc A, Camci C, Turk HM, Buyukberber S. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology. 2003;65:1-6.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 50]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
10.  Bergmann JF, Bidart JM, George M, Beaugrand M, Levy VG, Bohuon C. Elevation of CA 125 in patients with benign and malignant ascites. Cancer. 1987;59:213-217.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 1]  [Reference Citation Analysis (0)]
11.  Eerdekens MW, Nouwen EJ, Pollet DE, Briers TW, De Broe ME. Placental alkaline phosphatase and cancer antigen 125 in sera of patients with benign and malignant diseases. Clin Chem. 1985;31:687-690.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Collazos J, Genolla J, Ruibal A. CA 125 serum levels in patients with non-neoplastic liver diseases. A clinical and laboratory study. Scand J Clin Lab Invest. 1992;52:201-206.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 27]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
13.  Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117:215-220.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 416]  [Cited by in F6Publishing: 323]  [Article Influence: 10.1]  [Reference Citation Analysis (0)]